These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21439626)

  • 1. Hereditary angioedema: key role for kallikrein and bradykinin in vascular endothelial-cadherin cleavage and edema formation.
    Bouillet L; Mannic T; Arboleas M; Subileau M; Massot C; Drouet C; Huber P; Vilgrain I
    J Allergy Clin Immunol; 2011 Jul; 128(1):232-4. PubMed ID: 21439626
    [No Abstract]   [Full Text] [Related]  

  • 2. Vascular endothelial-cadherin: a possible link between endocytosis and ectodomain shedding.
    Zhang RY; Li L; Wu J; Tang YQ
    J Allergy Clin Immunol; 2012 Jan; 129(1):266; author reply 266-7. PubMed ID: 21982111
    [No Abstract]   [Full Text] [Related]  

  • 3. The bradykinin-forming cascade and its role in hereditary angioedema.
    Kaplan AP; Joseph K
    Ann Allergy Asthma Immunol; 2010 Mar; 104(3):193-204. PubMed ID: 20377108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma.
    Joseph K; Tuscano TB; Kaplan AP
    Ann Allergy Asthma Immunol; 2008 Sep; 101(3):279-86. PubMed ID: 18814451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary angioedema: a bradykinin-mediated swelling disorder.
    Björkqvist J; Sala-Cunill A; Renné T
    Thromb Haemost; 2013 Mar; 109(3):368-74. PubMed ID: 23306453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
    Hwang G; Johri A; Ng S; Craig T
    Immunotherapy; 2019 Aug; 11(11):937-944. PubMed ID: 31234673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular reactions in hereditary angioneurotic edema.
    Juhlin L; Michaëlsson G
    Acta Derm Venereol; 1969; 49(1):20-5. PubMed ID: 4182089
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis.
    Joseph K; Tholanikunnel TE; Kaplan AP
    Ann Allergy Asthma Immunol; 2010 Jan; 104(1):50-4. PubMed ID: 20143645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
    Cugno M; Zanichelli A; Foieni F; Caccia S; Cicardi M
    Trends Mol Med; 2009 Feb; 15(2):69-78. PubMed ID: 19162547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THE PERMEABILITY GLOBULINS OF HUMAN SERUM AND THE BIOCHEMICAL MECHANISM OF HEREDITARY ANGIONEUROTIC EDEMA.
    BECKER EL; KAGEN L
    Ann N Y Acad Sci; 1964 Aug; 116():866-73. PubMed ID: 14212859
    [No Abstract]   [Full Text] [Related]  

  • 11. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo.
    Oschatz C; Maas C; Lecher B; Jansen T; Björkqvist J; Tradler T; Sedlmeier R; Burfeind P; Cichon S; Hammerschmidt S; Müller-Esterl W; Wuillemin WA; Nilsson G; Renné T
    Immunity; 2011 Feb; 34(2):258-68. PubMed ID: 21349432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ecallantide for the treatment of acute attacks in hereditary angioedema.
    Cicardi M; Levy RJ; McNeil DL; Li HH; Sheffer AL; Campion M; Horn PT; Pullman WE
    N Engl J Med; 2010 Aug; 363(6):523-31. PubMed ID: 20818887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angioedema and the role of bradykinins: new treatments and implications in patients with heart failure].
    Mansi M; Wu MA; Zanichelli A; Cicardi M
    G Ital Cardiol (Rome); 2016 Dec; 17(12):966-972. PubMed ID: 28151501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathogenesis of hereditary angioedema.
    Davis AE
    Transfus Apher Sci; 2003 Dec; 29(3):195-203. PubMed ID: 14572810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hageman factor-dependent pathways: mechanism of initiation and bradykinin formation.
    Kaplan AP
    Fed Proc; 1983 Nov; 42(14):3123-7. PubMed ID: 6556144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary angioedema: examining the landscape of therapies and preclinical therapeutic targets.
    Farkas H
    Expert Opin Ther Targets; 2019 Jun; 23(6):457-459. PubMed ID: 31018718
    [No Abstract]   [Full Text] [Related]  

  • 17. Hereditary angioedema: Looking for bradykinin production and triggers of vascular permeability.
    Margaglione M; D'Apolito M; Santocroce R; Maffione AB
    Clin Exp Allergy; 2019 Nov; 49(11):1395-1402. PubMed ID: 31574187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.
    Sheffer AL; Campion M; Levy RJ; Li HH; Horn PT; Pullman WE
    J Allergy Clin Immunol; 2011 Jul; 128(1):153-159.e4. PubMed ID: 21481442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid.
    Charlesworth MC; Young CY; Miller VM; Tindall DJ
    J Androl; 1999; 20(2):220-9. PubMed ID: 10232657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of endothelial microparticles in patients with heart failure.
    Nozaki T; Sugiyama S; Sugamura K; Ohba K; Matsuzawa Y; Konishi M; Matsubara J; Akiyama E; Sumida H; Matsui K; Jinnouchi H; Ogawa H
    Eur J Heart Fail; 2010 Nov; 12(11):1223-8. PubMed ID: 20817695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.